Not Signed In - BioCryst Initiates Phase II Influenza Clinical Trial To Evaluate Peramivir
Fri, 26 Jan 2007 08:00 AM EST
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated a Phase II clinical trial of peramivir, the company's lead influenza neuraminidase inhibitor, to determine the safety and efficacy of an intramuscular formulation of the drug in patients with influenza. [click link for full article] ...
Related Topics
- Clinical Trials
- Influenza
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Influenza and Colds
- Tarceva
- Nystatin and Triamcinolone
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Patient Issues
- Kniest dysplasia
- Influenza Virus Vaccine
- Influenza (Flu)
- Influenza Vaccines
- H1N1 (swine) influenza
email this page
print this page
bookmark this page
feedback on this page
